Treatment decisions and discontinuation of palliative chemotherapy near the end-of-life, in relation to socioeconomic variables

Acta Oncologica

Volumn 52, Issue 6, 2013, Pages 1062-1066

  Randén, Margareta ^a,b   Helde Frankling, Maria ^c   Runesdotter, Sara ^b   Strang, Peter ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Stockholms Sjukhem Foundation   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; ERLOTINIB; ETOPOSIDE;

ADULT; AGED; ARTICLE; BONE MARROW DEPRESSION; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DISEASE COURSE; DISSEMINATED CANCER; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HOME CARE; HUMAN; INTESTINE CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; SKIN CANCER; SOCIAL STATUS; TERMINAL CARE; TREATMENT WITHDRAWAL; AGE; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COHABITATION; DEATH; EDUCATIONAL STATUS; MARRIED PERSON; MEDICAL RECORD; PALLIATIVE THERAPY;

EID: 84880278345     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.758872     Document Type: Article

References (34)

1. Bergh J. Q uo vadis with targeted drugs in the 21st century? J Clin Oncol 2009; 27: 2-5.
2. Hudis C A. T rastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
3. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, et al. Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 2004; 22: 3302-8.
4. Renouf D, Kennecke H, Gill S. T rends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer 2008; 7: 386-9.
5. Cancerfonden. C ancerfondsrapporten (Swe). S tockholm: The Swedish Cancer Society; 2011. pp. 132.
6. Earle C C, Neville B A, Landrum M B, Ayanian J Z, Block S D, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004; 22: 315-21.
7. Nappa U, Lindqvist O, Rasmussen BH, Axelsson B. P alliative chemotherapy during the last month of life. Ann Oncol 2011; 22: 2375-80.
8. Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare benefi ciaries at the end of life. Ann Intern Med 2003; 138: 639-43.
9. Christakis N A, Lamont E B. E xtent and determinants of error in doctors prognoses in terminally ill patients: Prospective cohort study. BMJ 2000; 320: 469-72.
10. Harrington S E, Smith TJ. The role of chemotherapy at the end of life: "When is enough, enough?" JAMA 2008; 299: 2667-78.
11. Murillo J R, Jr., K oeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 2006;11:1095-9.
12. Browner I, Carducci M A. P alliative chemotherapy: Historical perspective, applications, and controversies. Semin Oncol 2005; 32: 145-55.
13. Chochinov HM, Tataryn DJ, Wilson KG, Ennis M, Lander S. Prognostic awareness and the terminally ill. Psychosomatics 2000; 41: 500-4.
14. Chu DT, Kim SW, Kuo HP, Ozacar R, Salajka F, Krishnamurthy S, et al. Patient attitudes towards chemotherapy as assessed by patient versus physician: A prospective observational study in advanced non-small cell lung cancer. Lung Cancer 2007; 56: 433-43.
15. Matsuyama R, Reddy S, Smith TJ. W hy do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 2006; 24: 3490-6.
16. Saviani-Zeoti F, Petean EB. B reaking bad news: Doctors feelings and behaviors. Span J Psychol 2007; 10: 380-7.
17. Bernheim SM, Ross JS, Krumholz HM, Bradley EH. I nfl uence of patients socioeconomic status on clinical management decisions: A qualitative study. Ann Fam Med 2008; 6: 53-9.
18. Byers T E, Wolf HJ, Bauer KR, Bolick-Aldrich S, Chen VW, Finch JL, et al. The impact of socioeconomic status on survival after cancer in the United States: Findings from the National Program of Cancer Registries Patterns of Care Study. Cancer 2008; 113: 582-91.
19. Cavalli-Bjorkman N, Lambe M, Eaker S, Sandin F, Glimelius B. Differences according to educational level in the management and survival of colorectal cancer in Sweden. Eur J Cancer 2011; 47: 1398-406.
20. Albano JD, Ward E, Jemal A, Anderson R, Cokkinides VE, Murray T, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst 2007; 99: 1384-94.
21. Walston J, Hadley E C, Ferrucci L, Guralnik J M, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: Toward a better understanding of physiology and etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 2006; 54: 991-1001.
22. Cavalli-Bjorkman N, Glimelius B, Strang P. E qual cancer treatment regardless of education level and family support? A qualitative study of oncologists decision-making. BMJ Open 2012; 2: E001248.
23. Singer T. The past, present and future of social neuroscience: A European perspective. Neuroimage 2012; 61: 437-49.
24. Dapretto M, Davies MS, Pfeifer JH, Scott A A, Sigman M, Bookheimer SY, et al. Understanding emotions in others: Mirror neuron dysfunction in children with autism spectrum disorders. Nat Neurosci 2006; 9: 28-30.
25. Rizzolatti G. The mirror neuron system and its function in humans. Anat Embryol (Berl) 2005; 210: 419-21.
26. Street RL, Jr., O 'Malley KJ, Cooper LA, Haidet P. Understanding concordance in patient-physician relationships: Personal and ethnic dimensions of shared identity. Ann Fam Med 2008; 6: 198-205.
27. Chang SM, Barker FG, 2nd. M arital status, treatment, and survival in patients with glioblastoma multiforme: A population based study. Cancer 2005; 104: 1975-84.
28. Pinquart M, Duberstein PR. A ssociations of social networks with cancer mortality: A meta-analysis. Crit Rev Oncol Hematol 2010; 75: 122-37.
29. Bhargava A, D u X L. R acial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer 2009; 115: 2999-3008.
30. Obeidat NA, Pradel FG, Zuckerman IH, Trovato JA, Palumbo FB, DeLisle S, et al. Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. Am J Manag Care 2010; 16: 515-22.
31. Weeks J C, Catalano P J, Cronin A, Finkelman M D, Mack J W, Keating NL, et al. Patients expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367: 1616-25.
32. Back AL, Arnold RM, Baile WF, Tulsky JA, Fryer-Edwards K. Approaching diffi cult communication tasks in oncology. CA Cancer J Clin 2005; 55: 164-77.
33. Baider L, Wein S. R eality and fugues in physicians facing death: Confrontation, coping, and adaptation at the bedside. Crit Rev Oncol Hematol 2001; 40: 97-103.
34. Ptacek J T, Eberhardt TL. B reaking bad news. A review of the literature. JAMA 1996; 276: 496-502.